Your browser doesn't support javascript.
loading
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Zhang, Pin; Zhang, Qingyuan; Tong, Zhongsheng; Sun, Tao; Li, Wei; Ouyang, Quchang; Hu, Xichun; Cheng, Ying; Yan, Min; Pan, Yueyin; Teng, Yuee; Yan, Xi; Wang, Ying; Xie, Weimin; Zeng, Xiaohua; Wang, Xiaojia; Hu, Changlu; Geng, Cuizhi; Zhang, Hongwei; Li, Wenxin; Wu, Xinhong; Zhong, Jincai; Xu, Jingwei; Shi, Yanxia; Wei, Wenhua; Bayaxi, Nayima; Zhu, Xiaoyu; Xu, Binghe.
Affiliation
  • Zhang P; Department of Medical Oncology and Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Zhang Q; Ward One of Mammary Department, Harbin Medical University Cancer Hospital, Harbin, China.
  • Tong Z; Breast Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Sun T; Breast Internal Medicine Department, Liaoning Cancer Hospital and Institute, Shenyang, China.
  • Li W; Department of Medical Oncology, The First Hospital of Jilin University, Changchun, China.
  • Ouyang Q; Breast Internal Medicine Department, Hunan Cancer Hospital, Changsha, China.
  • Hu X; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Cheng Y; Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, China.
  • Yan M; Department of Breast, Henan Cancer Hospital, Zhengzhou, China.
  • Pan Y; Oncology Chemotherapy Department First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, China.
  • Teng Y; Department of Medical Oncology, First Hospital of China Medical University, Shenyang, China.
  • Yan X; Department of Head and Neck Cancer, West China Hospital, Sichuan University, Chengdu, China.
  • Wang Y; Phase I Clinical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Xie W; Breast, Bone and Soft Tissue Oncology, Guangxi Medical University Cancer Hospital, Nanning, China.
  • Zeng X; Breast Cancer Center, Chongqing University Cancer Hospital, Chongqing, China.
  • Wang X; Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
  • Hu C; The Fourth Ward of Medical Oncology, Anhui Provincial Cancer Hospital, Hefei, China.
  • Geng C; Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Zhang H; General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Li W; Medical Oncology, Inner Mongolia Autonomous Region People's Hospital, Hohhot, China.
  • Wu X; Department of Breast Oncology, Hubei Cancer Hospital, Wuhan, China.
  • Zhong J; Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Xu J; Breast Surgery, The Second Hospital of Jilin University, Changchun, China.
  • Shi Y; Department of Internal Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Wei W; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, China.
  • Bayaxi N; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, China.
  • Zhu X; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, China.
  • Xu B; Department of Medical Oncology and Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: xubinghe@medmail.com.cn.
Lancet Oncol ; 24(6): 646-657, 2023 06.
Article in En | MEDLINE | ID: mdl-37182538
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Clinical_trials Limits: Female / Humans Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2023 Type: Article Affiliation country: China
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Clinical_trials Limits: Female / Humans Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2023 Type: Article Affiliation country: China